- X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
- X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia
- Hercules Capital Reports First Quarter 2019 Financial Results
- X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer
- X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
- X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
- Imara Appoints Chief Financial & Chief Operating Officer
- X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
- X4 Pharmaceuticals Provides Business and Clinical Development Update
X4 Pharmaceuticals Inc (XFOR:NAQ) closed at 14.63, 112.03% above the 52 week low of 6.90 set on Nov 14, 2018.
6.90Nov 14 2018112.44Jun 25 2018
Markit short selling activity
|Market cap||181.34m USD|
|EPS (TTM)||-20.25 |
Data delayed at least 15 minutes, as of Jun 25 2019 21:00 BST.